During the 3rd European Myeloma Network Meeting, the Multiple Myeloma hub was pleased to speak to Bruno Paiva, University of Navarra, Pamplona, ES. We asked, How is the definition of high-risk multiple myeloma (MM) evolving?
Paiva begins by explaining how the evolution of defining high-risk MM has been positive over the past few decades, which could lead to significant improvements in how patients are staged in the future. The starting point for defining high-risk MM is a Revised International Staging System (R-ISS) Stage 3. Paiva states that this is effective; however, there is room for improvement, either by increasing the accuracy of risk stratification at baseline or after treatment, for example by assessing additional cytogenetic abnormalities, analyzing tumor burden, and evaluating minimal residual disease.
